Stay updated on Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial
Sign up to get notified when there's something new on the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page.

Latest updates to the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page
- Check5 days agoChange DetectedA service alert has been added regarding planned maintenance on July 26th, indicating that most services will be unavailable for over 12 hours starting at 6 AM EDT.SummaryDifference4%
- Check12 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.SummaryDifference5%
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference4%
- Check34 days agoChange DetectedThe web page has been updated from version v2.16.1 to v2.16.2.SummaryDifference0.3%
- Check48 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference6%
- Check55 days agoChange DetectedThe content regarding 'Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)' has been completely removed from the page.SummaryDifference0.3%
Stay in the know with updates to Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page.